Congressional Testimony

1997

September

• Fred Shank, Ph.D., September 25, 1997
  Director, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Subcommittee on Human Resources on the potential human health threats that may be posed by Pfiesteria via human consumption of seafood.
• Dr. Thomas Shope, September 25, 1997
  Acting Director, Division of Electronics and Computer Science before the subcommittee on Oversight and Investigations, Committee on Veteran's Affairs, U.S. House of Representative on "Year 2000" date issue as it related to medical devices.

July

• Dr. Kathryn C. Zoon, July 31, 1997
  Director, Center for Biologics Evaluation and Research, FDA, before the Subcommittee on Human Resources and Intergovernmental Relations. Safety implications of plasma pool sizes in the manufacture of fractionated blood products.
• Dr. Murray M. Lumpkin, July 30, 1997
  Deputy Director for Review Management, Center for Drug Evaluation and Research, FDA, DHHS, before the Subcommittee on Health and Environment, Committee on Commerce, U.S. House of Representatives on the implementation of Title VI of the Clean Air Act.

June

• Dr. Thomas Shope, June 26, 1997
  Acting Director, Division of Electronics and Computer Science before the subcommittee on Oversight and Investigations, Committee on Veteran's Affairs, U.S. House of Representative on "Year 2000" date issue as it related to medical devices.
• Dr. Michael A. Friedman, June 5, 1997
  Lead Deputy Commissioner of Food and Drug Administration before the Subcommittee on Human Resources and Intergovernmental relations U.S. House of Representatives on FDA's role in regulating and protecting the nation's blood supply.

May

• Mary K. Pendergast, May 8, 1997
  Deputy Commissioner and Senior Advisor to the Commissioner of Food and Drugs, before the subcommittee on human resources to discuss the Agency's policies with respect to the protection of human subjects in biomedical research.

April

• Dr. Michael A. Friedman, April 30, 1997
  Lead Deputy Commissioner, Food and Drug Administration before the Subcommittee on Health and The Environment on Reauthorization of the FDA's Medical Device Program.
• Dr. Michael A. Friedman, April 23, 1997
  Food and Drug Administration before the Subcommittee on Health and The Environment on Reauthorization of the Prescription Drug User Fee Act of 1992.

March

• Dr. Michael A. Friedman, March 19, 1997
  Deputy Commissioner for Operations, Food and Drug Administration before the Committee on Labor and Human Resources on FDA's Accomplishments and Proposals.

February

• William B. Schultz, February 6, 1997
  Deputy Commissioner for Policy, Food and Drug Administration, before the Subcommittee on Oversight and Investigations on FDA's regulation of products that can be used in the home and in other nonprofessional settings (over-the-counter (OTC))to test for drugs of abuse.

January

• Dr. Michael A. Friedman, January 29, 1997
  Deputy Commissioner for Operations, Food and Drug Administration, Committee on Government Reform and Oversight to discuss proposed rule on the ruminant to ruminant feed ban and the potential transmission of spongiform encephalopathies to humans.